

## Is Bariatric Surgery an Effective Treatment for Type II Diabetic Kidney Disease?

Allon N. Friedman\* and Bruce Wolfe†

### Abstract

Type II diabetic kidney disease is devastating to patients and society alike. This review will evaluate bariatric surgery as a treatment for diabetic kidney disease primarily through its ability to induce and maintain regression of type II diabetes. The review begins by outlining the global challenge of diabetic kidney disease, its link to obesity, and the comparative benefits of bariatric surgery on weight and type II diabetes. It then surveys comprehensively the relevant literature, which reports that although bariatric surgery is associated with reductions in albuminuria, its effect on harder clinical end points like progression of diabetic kidney disease is not known. The review also includes a critical assessment of the risks and costs of bariatric surgery and concludes by acknowledging the major knowledge gaps in the field and providing research strategies to overcome them. Until these knowledge gaps are filled, clinicians will be forced to rely on their own subjective judgment in determining the benefit-risk ratio of bariatric surgery for patients with diabetic kidney disease.

*Clin J Am Soc Nephrol* 11: 528–535, 2016. doi: 10.2215/CJN.07670715

### Introduction

Type II diabetic kidney disease (DKD) presents a challenge for nephrologists in light of its high prevalence (1), its pronounced adverse effects on clinical outcomes, and its enormous effect on health care costs and resources. Unfortunately, current treatment options for DKD, which are primarily pharmacologic in nature, have only modest effects on its progression (1) and are associated with costs and side effects that often limit their use.

An alternative and less recognized approach to treating DKD involves weight reduction. Because obesity is believed to be intimately linked to the development of diabetes, reversing obesity through weight loss may in theory be an effective tool not only in slowing disease progression but curing it altogether. Of all of the weight reduction strategies available, bariatric surgery is by far the most effective and sustained and has even been shown in some patients to induce remission of diabetes. However, the weight loss approach to treating type II DKD is understudied by nephrologists (2).

This article will critically analyze the available literature to determine if bariatric surgery is an effective treatment for DKD. It will also address any knowledge gaps and practical issues that need to be addressed before adopting bariatric surgery as a mainstream treatment. Although weight loss may have potentially salutary effects on kidney health that are independent of its effects on diabetes (3), this topic is beyond the scope of this article and will not be addressed.

### The Challenge of DKD

Type II DKD is believed to be the leading global cause of kidney failure (4). In the United States, it

accounts for more than one of every two new cases of ESRD (5), with several other countries having even higher rates (5). The presence of DKD confers a markedly increased risk of cardiovascular events and death. Patients with diabetes and CKD have a 31% 10-year incidence of all-cause mortality and 20% incidence of cardiovascular mortality (6). These rates are far higher than the corresponding rates for patients with nondiabetic CKD, which itself is a high-risk group. DKD also accounts for a greatly disproportionate portion of health care dollars, totaling many billions annually (7).

Treatment options for DKD revolve around control of dysglycemia and BP (the latter preferably by inhibition of the renin-angiotensin-aldosterone axis). However, the evidence to support these interventions is mixed (2). In fact, the standard approach has failed to stem the rising prevalence of DKD, despite its use in growing numbers of patients with type II diabetes (1). Recent attempts to identify alternative drug therapies for DKD have also failed (8). There is, therefore, an immediate need to consider alternative approaches to prevent the development and progression of DKD.

### Obesity and the Development of DKD

Although the precise pathophysiology of DKD is not fully understood, it seems that excess weight is a key factor in the development of type II diabetes. In the majority of patients, weight gain precedes and is strongly predictive of type II diabetes (9,10). This is elegantly depicted in a Centers for Disease Control survey of the United States population between 1994 and 2013 that found the prevalence of diabetes lagging very closely behind that of obesity (as defined

\*Department of Medicine, Indiana University School of Medicine, Indianapolis, Indiana; and †Department of Surgery, Oregon Health and Science University, Portland, Oregon

### Correspondence:

Dr. Allon N. Friedman, Indiana University School of Medicine, 550 University Boulevard, Suite 6100, Indianapolis, IN 46202. Email: allfried@iu.edu

by body mass index [BMI] of  $\geq 30$  kg/m<sup>2</sup>) (10). The presence of type II diabetes is, in turn, by definition a necessary requirement for the development of DKD. The converse of these observations is likely also true. Weight reduction has the potential to induce remission of type II diabetes (see below), and correction of the diabetic milieu is expected to induce regression of DKD. The latter point was suggested by findings in eight patients with type I diabetic nephropathy who underwent pancreas transplantation with subsequent resolution of their diabetes. Kidney biopsies 10 years later showed reversal of their diabetic kidney lesions (11). This example supports the concept that the essential ingredient in curing DKD is inducing remission of diabetes, regardless of how it is done. As will be discussed, in overweight or obese patients with type II diabetes large weight reduction can sometimes accomplish this goal.

The facts above raise the possibility that by inducing regression or remission of type II diabetes weight reduction may represent an alternative approach to treat DKD. Although the precise numbers of patients with DKD suffering from excess adiposity are not known, obesity is very common in both the greater diabetes (approximately 90%) (12) and CKD (approximately 17%) (5) populations. Thus, a treatment strategy on the basis of weight reduction would likely be applicable to a large proportion of the populace with DKD.

### Comparative Effect of Bariatric Surgery on Weight and Remission of Diabetes

Weight reduction can be achieved by nonsurgical interventions (pharmacotherapy and dietary and lifestyle changes) or with what has become an increasingly accepted option, bariatric surgery. According to the American Society for Metabolic and Bariatric Surgery (ASMBS), approximately 179,000 bariatric procedures were carried out in the United States in 2013 in patients who were likely to have met standard qualifying criteria: BMI  $\geq 40$ ; BMI  $\geq 35$  and at least two obesity-related comorbidities (including type II diabetes); and inability to achieve a healthy sustained weight loss despite efforts to do so. The term bariatric surgery actually encompasses several specific procedures as shown in Figure 1. According to the ASMBS, sleeve gastrectomy and Roux-en-Y gastric bypass are currently the two most commonly performed (42% and 34%, respectively).

Of all of the available weight loss strategies, bariatric surgery unquestionably offers the most intensive and durable results. A meta-analysis including 11 clinical trials that randomized obese participants to bariatric surgery versus nonsurgical treatment for weight reduction with at least 6 months of follow-up found that patients in the surgery arm lost significantly more weight (mean difference, 26 kg;  $P < 0.001$ ) and that the difference was more pronounced in heavier patients (*i.e.*, BMI  $> 40$  kg/m<sup>2</sup>; mean difference, 31 kg) (13). This finding is consistent in the medical literature and should not be surprising, in part because nonsurgical weight reduction methods offer, on average, only modest weight reduction. This fact was shown in the seminal National Institutes of Health (NIH)-sponsored multicenter randomized trial Action for Health in Diabetes (Look AHEAD), which was designed to compare the effects of an intensive lifestyle intervention versus standard education


and support (control arm) on weight and clinical outcomes in 5145 overweight or obese patients with type II diabetes. By year 10 of follow-up, mean weight loss was 6% (approximately 6 kg) in the intervention group and 3.5% in controls (14). Of note, 6% mean weight loss is likely to represent the upper end of what can be achieved by lifestyle interventions, because weight loss may be more challenging outside the auspices of a clinical trial. Similarly, pharmacotherapy for obesity offers similarly modest average weight loss results (15) with added safety concerns (16).

How do nonsurgical and surgical strategies compare in terms of inducing remission of type II diabetes? The fact that an intensive lifestyle intervention for weight loss has only minimal influence on diabetes was shown conclusively in Look AHEAD (17). In that study, partial and complete remission of diabetes were defined as transitioning to a prediabetes level of glycemia (fasting plasma glucose of 100–126 mg/dl and hemoglobin A1c [HbA1c] of 5.7%–6.5%) or full normalization of glucose levels (fasting plasma glucose  $< 100$  mg/dl and HbA1c  $< 5.7\%$ ), respectively, when off of diabetes medications. After 1 year (the point of peak weight loss), only 11.5% of participants in the intervention group had a partial or complete remission of diabetes. This fell to 7.3% in year 4, with only 3.5% having a complete remission.

In contrast, two separate meta-analyses of randomized controlled trials and/or nonrandomized observational studies in patients with type II diabetes found that bariatric surgery was much more effective in inducing remission of diabetes compared with nonsurgical therapy (odds ratio, 14.1 [95% confidence interval, 6.7 to 29.9] [18]; relative risk, 22.1 [95% confidence interval, 3.2 to 154.3] [13]). A limitation of these findings was related to differences in the definition of remission, making it more difficult to objectively compare interventions.

The largest such randomized trial, very recently published and not included in the meta-analyses above (19), compared intensive lifestyle and medical management without and with a gastric bypass in 120 obese patients with type II diabetes. Over a 24-month follow-up period, the gastric bypass group lost 17% more of their baseline weight than the nonsurgical group. At 24 months, 42% of patients in the surgery group had partial remission (HbA1c  $\leq 6.5\%$  off of diabetes medications) of diabetes, and 25% had full remission (HbA1c  $\leq 6.0\%$  off of diabetes medications) compared with 0% and 0%, respectively, in the nonsurgical group. Of note, Ikramuddin *et al.* (19) used the American Diabetes Association definition for remission. An even more recently published randomized trial of 61 obese participants with longer follow-up (36 months) echoed these findings (20). The results of these studies suggest that if there is any possibility of treating DKD through remitting the underlying diabetes by weight loss, bariatric surgery is by far the most effective such strategy available. Interestingly, even before these data were published, the American Diabetes Association recommended bariatric surgery for patients who had type II diabetes that could not be controlled by nonsurgical methods (21).

Of note, the individual bariatric procedures (Figure 1) differ in terms of their effects. The greatest amount and durability of weight lost as well as degree of remission of



**Figure 1.** | Bariatric surgery procedures for the treatment of severe obesity. (A) Laparoscopic adjustable gastric banding, (B) sleeve gastrectomy, (C) Roux-en-Y gastric bypass, and (D) biliopancreatic diversion with duodenal switch. Reprinted from reference 42, with permission.

diabetes occur with the (infrequently used) biliopancreatic diversion with duodenal switch followed, in order, by the Roux-en-Y gastric bypass, sleeve gastrectomy, and gastric banding (22). One finding common to all bariatric surgeries is that, over time and on average, patients regain some of the weight that they initially lost. For example, in one prominent study that included over 4000 patients undergoing bariatric surgery, change in weight at 1 and 10 years

postsurgery was  $-38 \pm 7\%$  and  $-25 \pm 11\%$ , respectively, in the gastric bypass group, and  $-21 \pm 10\%$  and  $-13 \pm 13\%$ , respectively, in gastric banding patients.

#### How Does Bariatric Surgery Remit Diabetes?

The mechanism(s) underlying bariatric surgery's powerful effects on weight and metabolic parameters,

including regression of diabetes, are important to understand, because they might lead to newer, less invasive therapies for DKD. The traditional view has been that the effects are a direct result of mechanical or anatomic changes associated with the surgical procedure itself. Hence, bariatric surgery procedures were previously categorized into restrictive and malabsorptive categories. A growing body of research now finds this perspective to be outdated. Ongoing investigations are now beginning to piece together a much more complex picture that involves postsurgical changes leading to adaptations in the gut that are modulated by its own hormonal and nervous systems interacting with gut microbes, bile acids, and nutrient delivery (23).

### Effect of Bariatric Surgery on DKD

There are several reasons why bariatric surgery may have the potential to ameliorate DKD. First and foremost, postsurgical regression of diabetes is expected to retard or possibly even reverse the still incompletely understood mechanisms through which chronic dysglycemia damages the kidney. In addition, putative risk factors for kidney disease, like hypertension, hyperinsulinemia and insulin resistance, dyslipidemia, and glomerular hyperfiltration, are also improved after surgery (20,24–27). However, the literature in this area is presently too handicapped by limitations—small sample sizes, relatively short-term follow-up periods, lack of control groups, and inclusion of patients identified as having DKD solely on the basis of elevations in albuminuria or proteinuria—to tease out how, if at all, bariatric surgery improves DKD.

The literature describing the effects of bariatric surgery on renal parameters in patients with type II diabetes or overt DKD is shown in Table 1. The fact that all of the reports were published within the past 10 years attests to growing interest in this topic. The most consistent finding is that albuminuria and proteinuria levels fall after surgery, with most studies also showing a reduction in serum creatinine. Although these findings seem to be salutary on the surface, their implications are uncertain, because they may simply be reflecting changes in renal physiology unrelated to the pathophysiology of DKD. For example, the reduction in proteinuria and albuminuria could be caused by lower glomerular filtration that is commonly seen after bariatric surgery (26). Whether this represents a protective effect against DKD is not known (28). Similarly, the observed improvement (*i.e.*, drop) in serum creatinine is most likely caused by loss of lean body mass (and subsequent reduced generation of creatinine) that coincides with large weight loss rather than a clear effect on glomerular filtration (26).

What is notable about the literature in this area is the lack of data on whether bariatric surgery influences major clinical end points, like progression of DKD, development of ESRD, or other major outcomes, like hospitalization and death.

### Bariatric Surgery to Treat DKD: Epidemiologic Data

No population-based epidemiologic surveys exist of patients with DKD undergoing bariatric surgery. Studies of

bariatric surgery in the broader CKD population, which includes patients on dialysis and patients with kidney transplants are, therefore, the next best available source of information.

From 2002 to 2011, 1114 patients on dialysis and 395 patients with kidney transplants ages 20 years old and older who were insured by Medicare underwent bariatric surgery (5). Approximately 60% of the surgeries were gastric bypasses, with gastric banding making up almost all of the remaining surgeries; 42% of the patients had diabetes, and of these, 81% had a BMI of  $\geq 35$  kg/m<sup>2</sup>. After surgery, the mean BMI dropped from 44 kg/m<sup>2</sup> to around 35 kg/m<sup>2</sup> at 18 months, where it remained. Thus, bariatric surgery seems to be highly effective in inducing large weight loss in patients with CKD. Whether it improves kidney function or other major end points in such patients is still unknown.

### Risks and Costs of Bariatric Surgery for DKD

Any serious consideration of using bariatric surgery to treat DKD must account for the associated risks and costs. As in the previous section, studies in the CKD populace will be used to assess such risks because of the lack of data on patients with DKD.

Bariatric surgery carries with it a 30-day perioperative mortality risk of about 0.1%–0.2% (29,30), with a 3-year all-cause mortality rate of 0.9% (30). Patients with stages II–V CKD have a similar 30-day mortality rate (31), although a higher rate (1.3%) has been reported in patients with ESRD (5). Longer-term all-cause mortality rates for patients with CKD are not available whereas for patients with ESRD the probabilities of overall survival at 1 and 3 years were 90% and 79%, respectively, between 2002 and 2011 (5). Of note, the presence of DKD alone is associated with a striking 10-year mortality rate of  $\geq 50\%$  (6), with the rate increasing even further (66%) after dialysis is started. Notwithstanding the limited available data, it is therefore not implausible to expect that the longevity benefits of treating DKD with bariatric surgery could outweigh the mortality risks associated with surgery.

Bariatric surgery is also associated with complications that are directly related (bleeding, stomal stenosis, leaks, wound healing, *etc.*) or unrelated (malnutrition, sepsis, thromboembolism, *etc.*) to the procedure itself. Complication and reoperation rates after bariatric surgery are 17% and 7%, respectively, in the general population (29). Interestingly, one large observational study found little, if any, relative increase in 30-day complications in patients with CKD (32). This conflicts with previous reports that the presences of preoperative kidney impairment and diabetes are associated with higher morbidity and mortality after major abdominal surgery (33) and a greater risk of AKI after bariatric surgery, respectively (34). Postoperative kidney stone formation is also a concern, particularly with procedures (Roux-en-Y gastric bypass and biliopancreatic diversion with duodenal switch) that affect oxalate and citrate excretion (35–37). A more severe manifestation of this process is oxalate nephropathy, which has even been associated with rapid progression to ESRD (38). All of these risks, including worsening of underlying DKD, must be considered when referring patients for bariatric surgery.

**Table 1. Effect of bariatric surgery on kidney-related parameters in patients with type II diabetes**

Type of Study	Type of Bariatric Surgery	No. of Subjects (with Type II Diabetes)	Follow-Up Period (mo)	Remission of Type II Diabetes, % <sup>a</sup>	Effect on GFR Markers	Effect on Albuminuria/Proteinuria	Effect on Clinical End Points
<b>Case reports</b>							
43	RYGB	1 (100%)	26	N/A	↓ sCr (1.4→1.2)	↓ Proteinuria (6.3→0.07 g/d)	N/A
44	RYGB	1 (100%)	3	100	↓ sCr (4.3→4.0)	↓ Proteinuria (5.9→0.8 g/d)	N/A
45	RYGB	1 (100%)	12	100	N/A	↓ Albuminuria (100→<2 mg/24 h)	N/A
46	RYGB, LAGB	2 (50%)	17–19	N/A	N/A	N/A	Renal function recovered, dialysis stopped
<b>Cohorts</b>							
47	RYGB	9 (56%)	24–48	N/A	Average sCr for two patients with diabetic nephropathy increased over time (approximately 1.8→2.7) No change in sCr	N/A	N/A
48	RYGB	94 (34%)	12 (mean)	N/A	No change in sCr	↓ Albuminuria (17→6 mg/g)	N/A
49	Not specified	25 (72%)	12–24	N/A	↓ sCr (1.4→1.2), increase in eGFR (48→62)	N/A	N/A
50	RYGB, others	15 (100%)	6	N/A	↓ sCr (0.8→0.6), no change in cystatin C	↓ Albuminuria (65→39 mg/g)	N/A
51	RYGB	35 (54%)	12	84	↓ 15% in 24-h CrCl, sCr, cystatin C	No change	N/A
52	BPD	22 (100%)	120	100	No change in sCr, eGFR	MA: 32%→0%	N/A
53	RYGB	56 (68%)	6–24+	N/A	↓ sCr (1.4→1.2) in mild DKD, ↑ in moderate DKD (2.2→2.7)	N/A	N/A
54	RYGB, SG, LAGB	52 (100%)	60–92	44	No change in sCr	↓ Albuminuria by 58% regression	N/A
55	LAGB	23 (100%)	30 (mean)	N/A	N/A	↓ Albuminuria (67→15 mg/g)	N/A
56	RYGB	131 (100%)	60–108	N/A	N/A	N/A	↓ Predicted 5-yr risk of developing nephropathy (57) (12%→6.6%)
25	RYGB, SG	97 (100%)	36	28	↓ sCr (0.7→0.6)	↓ MA by 70%	N/A
58	SG	5 (20%)	12	N/A	No change in sCr, cystatin C, eGFR (compared with control group)	No change in proteinuria (compared with control group)	N/A

**Table 1. (Continued)**

Type of Study	Type of Bariatric Surgery	No. of Subjects (with Type II Diabetes)	Follow-Up Period (mo)	Remission of Type II Diabetes, % <sup>a</sup>	Effect on GFR Markers	Effect on Albuminuria/Proteinuria	Effect on Clinical End Points
59	RYGB	70 (100%)	12–18	N/A	N/A	↓ Albuminuria (32→15 mg/g)	N/A

Type II diabetes mellitus was presumed if the type of diabetes (I versus II) was not openly stated in light of the well known relationship between obesity and type II diabetes. Units of measurement: creatinine clearance, ml/min; eGFR, ml/min per 1.37 m<sup>2</sup>; creatinine, mg/dl; cystatin C, mg/L. Upward arrows indicates increase; downward arrows indicates decrease; right-facing arrows indicates temporal progression of laboratory result. RYGB, Roux-en-Y gastric bypass; LAGB, laparoscopic adjustable lap banding; BPD, biliopancreatic diversion with duodenal switch; SG, sleeve gastrectomy; N/A, not applicable; sCr, serum creatinine; CrCl, creatinine clearance; DKD, diabetic kidney disease; MIA, microalbuminuria.

<sup>a</sup>On the basis of each study's definition.

Cost is another important consideration. Bariatric surgery costs approximately \$15,000–\$30,000 depending on the specific procedure and in the absence of rare but severe complications (39). This compares favorably to the long-term costs of progressive DKD (40), particularly if ESRD develops, where the annual cost is approximately \$70,000–\$90,000 (5). The key to cost savings would be to limit the bariatric option to higher-risk individuals at risk of progression.

**Areas of Uncertainty**

A number of important questions need to be addressed before recommending bariatric surgery as a treatment for DKD. First, does bariatric surgery actually slow progression of DKD? If so, which patients with DKD should be targeted for such an approach? Which bariatric procedure offers the best renoprotective effects? Are kidney-related benefits proportional to the weight lost? What effect does weight reaccumulation have on remission of DKD? Is actual remission required to treat DKD, or can more modest improvements suffice? What are the rates of complications and mortality after bariatric surgery in patients with DKD, and are these risks outweighed by the kidney-related and other benefits? What additional benefits, such as improvements in dialysis access placement or transplantation wait-listing rates, can bariatric surgery offer?

Answering these questions will be challenging. A recent NIH symposium on long-term outcomes in bariatric surgery (41) reviewed, in detail, the major hurdles in conducting well powered, randomized, controlled bariatric surgery trials, specifically with regard to recruitment, sample size, and length of follow-up. Given the current funding environment, it was felt that alternative research strategies, including large observational studies using existing or prospective databases, should be considered. This may be especially relevant when considering the extended length of time that it could take to reverse DKD (11). The authors of this article and associated collaborators are currently working on just such a strategy.

**Conclusions**

DKD is devastating to individuals and society. By inducing regression or remission of type II diabetes, bariatric surgery may also have the capability to effectively treat DKD. Small, short-term studies of bariatric surgery in patients with type II diabetes and DKD suggest a renoprotective effect primarily as reflected by a reduction in albuminuria, but effects on harder, more clinically relevant outcomes are lacking. The field is, therefore, ripe for clinical studies designed to elucidate the kidney-related benefits of bariatric surgery.

**Disclosures**

B.W. is an investigator in clinical trials funded by EnteroMedics. He has no personal compensation or interest in the company. A.N.F. has no disclosures.

**References**

- de Boer IH, Rue TC, Hall YN, Heagerty PJ, Weiss NS, Himmelfarb J: Temporal trends in the prevalence of diabetic kidney disease in the United States. *JAMA* 305: 2532–2539, 2011

2. Molitch ME, Adler AI, Flyvbjerg A, Nelson RG, So WY, Wanner C, Kasiske BL, Wheeler DC, de Zeeuw D, Mogensen CE: Diabetic kidney disease: A clinical update from Kidney Disease: Improving Global Outcomes. *Kidney Int* 87: 20–30, 2015
3. Friedman A: Implications and management of obesity in kidney disease. In: *Nutrition in Kidney Diseases*, edited by Byham-Gray L, Burrows J, Chertow G, New York, Springer, 2014
4. Atkins RC, Zimmet P: Diabetic kidney disease: Act now or pay later. *Kidney Int* 77: 375–377, 2010
5. US Renal Data System: *USRDS 2014 Annual Data Report: Atlas of End-Stage Renal Disease in the United States*, Bethesda, MD, National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, 2014
6. Afkarian M, Sachs MC, Kestenbaum B, Hirsch IB, Tuttle KR, Himmelfarb J, de Boer IH: Kidney disease and increased mortality risk in type 2 diabetes. *J Am Soc Nephrol* 24: 302–308, 2013
7. Foley RN, Collins AJ: The growing economic burden of diabetic kidney disease. *Curr Diab Rep* 9: 460–465, 2009
8. de Zeeuw D, Akizawa T, Audhya P, Bakris GL, Chin M, Christ-Schmidt H, Goldsberry A, Houser M, Krauth M, Lambers Heerspink HJ, McMurray JJ, Meyer CJ, Parving HH, Remuzzi G, Toto RD, Vaziri ND, Wanner C, Wittes J, Wrolstad D, Chertow GM; BEACON Trial Investigators: Bardoxolone methyl in type 2 diabetes and stage 4 chronic kidney disease. *N Engl J Med* 369: 2492–2503, 2013
9. American Diabetes Association: Diagnosis and classification of diabetes mellitus. *Diabetes Care* 36[Suppl 1]: S67–S74, 2013
10. Centers for Disease Control: Maps of Trends in Diagnosed Diabetes and Obesity. Available at: <http://www.cdc.gov/diabetes/statistics/>. Accessed September 24, 2015
11. Fioretto P, Steffes MW, Sutherland DE, Goetz FC, Mauer M: Reversal of lesions of diabetic nephropathy after pancreas transplantation. *N Engl J Med* 339: 69–75, 1998
12. World Health Organization: Obesity and Overweight Fact Sheet, 2013. Available at: [http://www.who.int/dietphysicalactivity/media/en/gfsf\\_obesity.pdf](http://www.who.int/dietphysicalactivity/media/en/gfsf_obesity.pdf). Accessed August 13, 2015
13. Gloy VL, Briel M, Bhatt DL, Kashyap SR, Schauer PR, Mingrone G, Bucher HC, Nordmann AJ: Bariatric surgery versus non-surgical treatment for obesity: A systematic review and meta-analysis of randomised controlled trials. *BMJ* 347: f5934, 2013
14. Wing RR, Bolin P, Brancati FL, Bray GA, Clark JM, Coday M, Crow RS, Curtis JM, Egan CM, Espeland MA, Evans M, Foreyt JP, Ghazarian S, Gregg EW, Harrison B, Hazuda HP, Hill JO, Horton ES, Hubbard VS, Jakicic JM, Jeffery RW, Johnson KC, Kahn SE, Kitabchi AE, Knowler WC, Lewis CE, Maschak-Carey BJ, Montez MG, Murillo A, Nathan DM, Patricio J, Peters A, Pi-Sunyer X, Pownall H, Reboussin D, Regensteiner JG, Rickman AD, Ryan DH, Safford M, Wadden TA, Wagenknecht LE, West DS, Williamson DF, Yanovski SZ; Look AHEAD Research Group: Cardiovascular effects of intensive lifestyle intervention in type 2 diabetes. *N Engl J Med* 369: 145–154, 2013
15. Van Gaal L, Scheen A: Weight management in type 2 diabetes: Current and emerging approaches to treatment. *Diabetes Care* 38: 1161–1172, 2015
16. Daubresse M, Alexander GC: The uphill battle facing antiobesity drugs. *Int J Obes* 39: 377–378, 2015
17. Gregg EW, Chen H, Wagenknecht LE, Clark JM, Delahanty LM, Bantle J, Pownall HJ, Johnson KC, Safford MM, Kitabchi AE, Pi-Sunyer FX, Wing RR, Bertoni AG; Look AHEAD Research Group: Association of an intensive lifestyle intervention with remission of type 2 diabetes. *JAMA* 308: 2489–2496, 2012
18. Müller-Stich BP, Senf J, Warschkow R, Kenngott HG, Billeter AT, Vit G, Helfert S, Diener MK, Fischer L, Büchler MW, Nawroth PP: Surgical versus medical treatment of type 2 diabetes mellitus in nonseverely obese patients: A systematic review and meta-analysis. *Ann Surg* 261: 421–429, 2015
19. Ikramuddin S, Billington CJ, Lee WJ, Bantle JP, Thomas AJ, Connett JE, Leslie DB, Inabnet WB 3rd, Jeffery RW, Chong K, Chuang LM, Sarr MG, Jensen MD, Vella A, Ahmed L, Belani K, Schone JL, Olofson AE, Bainbridge HA, Laqua PS, Wang Q, Korner J: Roux-en-Y gastric bypass for diabetes (the Diabetes Surgery Study): 2-year outcomes of a 5-year, randomised, controlled trial. *Lancet Diabetes Endocrinol* 3: 413–422, 2015
20. Courcoulas AP, Belle SH, Neiberg RH, Pierson SK, Eagleton JK, Kalarchian MA, DeLany JP, Lang W, Jakicic JM: Three-year outcomes of bariatric surgery vs lifestyle intervention for type 2 diabetes mellitus treatment: A randomized clinical trial [published online ahead of print July 1, 2015]. *JAMA Surg* doi: 10.1001/jamasurg.2015.1534
21. American Diabetes Association: Standards of medical care in diabetes—2013. *Diabetes Care* 36[Suppl 1]: S11–S66, 2013
22. Yu J, Zhou X, Li L, Li S, Tan J, Li Y, Sun X: The long-term effects of bariatric surgery for type 2 diabetes: Systematic review and meta-analysis of randomized and non-randomized evidence. *Obes Surg* 25: 143–158, 2015
23. Seeley RJ, Chambers AP, Sandoval DA: The role of gut adaptation in the potent effects of multiple bariatric surgeries on obesity and diabetes. *Cell Metab* 21: 369–378, 2015
24. Sjöström L, Lindroos AK, Peltonen M, Torgerson J, Bouchard C, Carlsson B, Dahlgren S, Larsson B, Narbro K, Sjöström CD, Sullivan M, Wedel H; Swedish Obese Subjects Study Scientific Group: Lifestyle, diabetes, and cardiovascular risk factors 10 years after bariatric surgery. *N Engl J Med* 351: 2683–2693, 2004
25. Schauer PR, Bhatt DL, Kirwan JP, Wolksi K, Brethauer SA, Navaneethan SD, Aminian A, Pothier CE, Kim ES, Nissen SE, Kashyap SR; STAMPEDE Investigators: Bariatric surgery versus intensive medical therapy for diabetes—3-year outcomes. *N Engl J Med* 370: 2002–2013, 2014
26. Friedman AN, Moe S, Fadel WF, Inman M, Mattar SG, Shihabi Z, Quinney SK: Predicting the glomerular filtration rate in bariatric surgery patients. *Am J Nephrol* 39: 8–15, 2014
27. Navaneethan SD, Malin SK, Arrigain S, Kashyap SR, Kirwan JP, Schauer PR: Bariatric surgery, kidney function, insulin resistance, and adipokines in patients with decreased GFR: A cohort study. *Am J Kidney Dis* 65: 345–347, 2015
28. Levey AS, Catran D, Friedman A, Miller WG, Sedor J, Tuttle K, Kasiske B, Hostetter T: Proteinuria as a surrogate outcome in CKD: Report of a scientific workshop sponsored by the National Kidney Foundation and the US Food and Drug Administration. *Am J Kidney Dis* 54: 205–226, 2009
29. Chang SH, Stoll CR, Song J, Varela JE, Eagon CJ, Colditz GA: The effectiveness and risks of bariatric surgery: An updated systematic review and meta-analysis, 2003–2012. *JAMA Surg* 149: 275–287, 2014
30. Courcoulas AP, Christian NJ, Belle SH, Berk PD, Flum DR, Garcia L, Horlick M, Kalarchian MA, King WC, Mitchell JE, Patterson EJ, Pender JR, Pomp A, Pories WJ, Thirlby RC, Yanovski SZ, Wolfe BM; Longitudinal Assessment of Bariatric Surgery (LABS) Consortium: Weight change and health outcomes at 3 years after bariatric surgery among individuals with severe obesity. *JAMA* 310: 2416–2425, 2013
31. Turgeon NA, Perez S, Mondestin M, Davis SS, Lin E, Tata S, Kirk AD, Larsen CP, Pearson TC, Sweeney JF: The impact of renal function on outcomes of bariatric surgery. *J Am Soc Nephrol* 23: 885–894, 2012
32. Saleh F, Kim SJ, Okrainec A, Jackson TD: Bariatric surgery in patients with reduced kidney function: An analysis of short-term outcomes. *Surg Obes Relat Dis* 11: 828–835, 2015
33. Cloyd JM, Ma Y, Morton JM, Kurella Tamura M, Poultsides GA, Visser BC: Does chronic kidney disease affect outcomes after major abdominal surgery? Results from the National Surgical Quality Improvement Program. *J Gastrointest Surg* 18: 605–612, 2014
34. Weingarten TN, Gurrieri C, McCaffrey JM, Rictor SJ, Hilgeman ML, Schroeder DR, Kendrick ML, Greene EL, Sprung J: Acute kidney injury following bariatric surgery. *Obes Surg* 23: 64–70, 2013
35. Lieske JC, Mehta RA, Milliner DS, Rule AD, Bergstralh EJ, Sarr MG: Kidney stones are common after bariatric surgery. *Kidney Int* 87: 839–845, 2015
36. Maalouf NM, Tondapu P, Guth ES, Livingston EH, Sakhaee K: Hypocitraturia and hyperoxaluria after Roux-en-Y gastric bypass surgery. *J Urol* 183: 1026–1030, 2010
37. Sinha MK, Collazo-Clavell ML, Rule A, Milliner DS, Nelson W, Sarr MG, Kumar R, Lieske JC: Hyperoxaluric nephrolithiasis is a complication of Roux-en-Y gastric bypass surgery. *Kidney Int* 72: 100–107, 2007
38. Nasr SH, D'Agati VD, Said SM, Stokes MB, Langoza MV, Radhakrishnan J, Markowitz GS: Oxalate nephropathy complicating Roux-en-Y Gastric Bypass: An underrecognized cause of

- irreversible renal failure. *Clin J Am Soc Nephrol* 3: 1676–1683, 2008
39. Maciejewski ML, Arterburn DE: Cost-effectiveness of bariatric surgery. *JAMA* 310: 742–743, 2013
  40. Nichols GA, Vupputuri S, Lau H: Medical care costs associated with progression of diabetic nephropathy. *Diabetes Care* 34: 2374–2378, 2011
  41. Courcoulas AP, Yanovski SZ, Bonds D, Eggerman TL, Horlick M, Staten MA, Arterburn DE: Long-term outcomes of bariatric surgery: A National Institutes of Health symposium. *JAMA Surg* 149: 1323–1329, 2014
  42. DeMaria EJ: Bariatric surgery for morbid obesity. *N Engl J Med* 356: 2176–2183, 2007
  43. Izzedine H, Coupaye M, Reach I, Deray G: Gastric bypass and resolution of proteinuria in an obese diabetic patient. *Diabet Med* 22: 1761–1762, 2005
  44. Agnani S, Vachharajani VT, Gupta R, Atray NK, Vachharajani TJ: Does treating obesity stabilize chronic kidney disease? *BMC Nephrol* 6: 7, 2005
  45. Pérez G, Devaud N, Escalona A, Downey P: Resolution of early stage diabetic nephropathy in an obese diabetic patient after gastric bypass. *Obes Surg* 16: 1388–1391, 2006
  46. Rubin J: Weight loss by bariatric surgery may permit patients with significant residual renal function to come off dialysis. Presented at the American Society of Nephrology Annual Conference, San Diego, CA, October 30–November 4, 2012
  47. Alexander JW, Goodman HR, Hawver LR, Cardi MA: Improvement and stabilization of chronic kidney disease after gastric bypass. *Surg Obes Relat Dis* 5: 237–241, 2009
  48. Agrawal V, Khan I, Rai B, Krause KR, Chengelis DL, Zalesin KC, Rocher LL, McCullough PA: The effect of weight loss after bariatric surgery on albuminuria. *Clin Nephrol* 70: 194–202, 2008
  49. Navaneethan SD, Yehnert H: Bariatric surgery and progression of chronic kidney disease. *Surg Obes Relat Dis* 5: 662–665, 2009
  50. Navaneethan SD, Kelly KR, Sabbagh F, Schauer PR, Kirwan JP, Kashyap SR: Urinary albumin excretion, HMW adiponectin, and insulin sensitivity in type 2 diabetic patients undergoing bariatric surgery. *Obes Surg* 20: 308–315, 2010
  51. Saliba J, Kasim NR, Tamboli RA, Isbell JM, Marks P, Feurer ID, Ikizler A, Abumrad NN: Roux-en-Y gastric bypass reverses renal glomerular but not tubular abnormalities in excessively obese diabetics. *Surgery* 147: 282–287, 2010
  52. Iaconelli A, Panunzi S, De Gaetano A, Manco M, Guidone C, Leccesi L, Gniuli D, Nanni G, Castagneto M, Ghirlanda G, Mingrone G: Effects of bilio-pancreatic diversion on diabetic complications: A 10-year follow-up. *Diabetes Care* 34: 561–567, 2011
  53. Schuster DP, Teodorescu M, Mikami D, Foreman K, Rogers P, Needleman BJ: Effect of bariatric surgery on normal and abnormal renal function. *Surg Obes Relat Dis* 7: 459–464, 2011
  54. Heneghan HM, Cetin D, Navaneethan SD, Orzech N, Brethauer SA, Schauer PR: Effects of bariatric surgery on diabetic nephropathy after 5 years of follow-up. *Surg Obes Relat Dis* 9: 7–14, 2013
  55. Stephenson DT, Jandeleit-Dahm K, Balkau B, Cohen N: Improvement in albuminuria in patients with type 2 diabetes after laparoscopic adjustable gastric banding. *Diab Vasc Dis Res* 10: 514–519, 2013
  56. Aminian A, Daigle CR, Romero-Talamás H, Kashyap SR, Kirwan JP, Brethauer SA, Schauer PR: Risk prediction of complications of metabolic syndrome before and 6 years after gastric bypass. *Surg Obes Relat Dis* 10: 576–582, 2014
  57. QKidney: QKidney 5-Year Nephropathy Risk Calculator. Available at: <http://www.qkidney.org/>. Accessed August 13, 2015
  58. MacLaughlin HL, Hall WL, Patel AG, Blacklock RM, Swift PA, Phanish MK, Dew T, Chowdhury P, Sanders TA, Macdougall IC: Weight loss, adipokines, and quality of life after sleeve gastrectomy in obese patients with stages 3–4 CKD: A randomized controlled pilot study. *Am J Kidney Dis* 64: 660–663, 2014
  59. Miras AD, Chuah LL, Khalil N, Nicotra A, Vusirikala A, Baqai N, Graham C, Ravindra S, Lascaratos G, Oliver N, le Roux CW: Type 2 diabetes mellitus and microvascular complications 1 year after Roux-en-Y gastric bypass: A case-control study. *Diabetologia* 58: 1443–1447, 2015
- Published online ahead of print. Publication date available at [www.cjasn.org](http://www.cjasn.org).